AstraZeneca AB (AZN) - יחס רווח גולמי

סמל תאגידי ולוגו של AstraZeneca Plc (AZN)

AstraZeneca PLC (AZN) growth is driven by an innovative pipeline and expansion into emerging markets. The operating gross margin confirms this trend, with the 74.10 metric serving as the target level. Business resilience relies on the demand for drugs treating rare pathologies. The holding's stability is guaranteed by an academic approach to R&D and the recruitment of leading scientists to develop life-saving medicines.

AZN (AstraZeneca PLC) היסטוריית שולי רווח גולמי מ-04.07.2022 עד 19.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור AstraZeneca Plc (AZN)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
ניתוח בסיסי של החברה:AstraZeneca
דוגמת מוצר של AstraZeneca

The scaling of the oncology portfolio at AstraZeneca PLC (AZN) is directly reflected in the dynamics of the gross operating margin. This indicator measures fundamental production efficiency, demonstrating the profit share after deducting direct costs. The calculation is performed by dividing the difference between revenue and cost of goods sold by total sales, which currently stands at 74.10. The stability of this value confirms low unit costs amid growth in global sales.